ChartMill assigns a Buy % Consensus number of 86% to AXSM. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-06 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-11-04 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-04 | Needham | Reiterate | Buy -> Buy |
| 2025-11-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-04 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-04 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-01 | B. Riley Securities | Initiate | Buy |
| 2025-08-05 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-05 | B of A Securities | Maintains | Buy -> Buy |
| 2025-08-04 | Needham | Reiterate | Buy -> Buy |
| 2025-06-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-09 | Needham | Maintains | Buy -> Buy |
| 2025-06-03 | Oppenheimer | Initiate | Outperform |
| 2025-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-06 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-06 | Baird | Maintains | Outperform -> Outperform |
| 2025-04-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-04-07 | Jefferies | Initiate | Buy |
| 2025-04-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-01 | Needham | Reiterate | Buy -> Buy |
| 2025-03-27 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-03-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-03 | Needham | Reiterate | Buy -> Buy |
| 2025-03-03 | Baird | Maintains | Outperform -> Outperform |
| 2025-02-27 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-02-26 | Mizuho | Maintains | Outperform -> Outperform |
26 analysts have analysed AXSM and the average price target is 180.65 USD. This implies a price increase of 20.88% is expected in the next year compared to the current price of 149.44.
The consensus rating for AXSOME THERAPEUTICS INC (AXSM) is 86.1538 / 100 . This indicates that analysts generally have a positive outlook on the stock.